Early Treatment Failure in Patients With Relapsed/Refractory Multiple Myeloma Receiving Bispecific T-Cell Engagers: Development and Validation of the CHARGE Prognostic Index
Purpose Outcomes with bispecific T-cell engagers (TCEs) in relapsed/refractory multiple myeloma (RRMM) are heterogeneous. A practical tool to guide prognosis is needed. We developed a model integrating clinical, biological, and treatment-related variables to predict progression-free survival (PFS) in patients receiving B-cell maturation antigen (BCMA)- or G-protein–coupled receptor class 5 member D-directed TCEs. Methods We evaluated outcomes of 577 BCMA-directed and 366 talquetamab treatments across 15 US Multiple Myeloma Immunotherapy Consortium centers. Variables significantly associated with inferior PFS in a multivariate Cox model were incorporated into a prognostic score and validated in an independent multicenter International Myeloma Foundation cohort. Results With a median follow-up of 8.4 months, the median PFS was 6.4 months (7.0 months for BCMA TCE; 6.1 months for talquetamab); 92% of patients were triple-class-refractory. Six variables significantly associated with inferior PFS—high-risk cytogenetic abnormalities (HRCAs) [del(17p) or ≥2 HRCAs], hyperferritinemia (≥600 ng/mL), anemia (hemoglobin <9 g/dL), early relapse (<18 months from frontline therapy), general performance status (Eastern Cooperative Oncology Group Performance Status ≥2), and exposure to prior BCMA-directed therapy—were combined to form the CHARGE index, stratifying patients into three risk groups. The median PFS was 21.8 months (95% CI, 11.7 to not reached), 7.1 months (95% CI, 6.1 to 10.1), and 1.6 months (95% CI, 1.2 to 2.5) in the low-, intermediate-, and high-risk groups, respectively; hazard ratios (HRs) were 2.0 (95% CI, 1.5 to 2.7) and 4.8 (95% CI, 3.5 to 6.7) for intermediate- and high-risk versus low-risk groups. External validation (n = 173) showed that the median PFS was not reached, 7.0 months, and 3.0 months, with corresponding HRs of 2.9 (95% CI, 1.7 to 4.9) and 4.8 (95% CI, 2.6 to 8.7). Conclusion The CHARGE index provides a simplified and externally validated framework for predicting treatment outcomes in patients with RRMM receiving TCEs.
Authors
- Jack Khouri (ORCID: https://orcid.org/0000-0002-2473-6528)
- Mahmoud Gaballa (ORCID: https://orcid.org/0000-0002-3928-6590)
- Luciano J. Costa (ORCID: https://orcid.org/0000-0001-5362-2469)
- Faiz Anwer (ORCID: https://orcid.org/0000-0001-6914-7439)
- Aimaz Afrough (ORCID: https://orcid.org/0000-0003-2645-8557)
- Saad Z. Usmani (ORCID: https://orcid.org/0000-0002-5484-8731)
- Christen M. Dillard (ORCID: https://orcid.org/0000-0002-7218-9960)
- Eli Zolotov (ORCID: https://orcid.org/0000-0003-3022-2547)
- Jana Mihályová (ORCID: https://orcid.org/0000-0001-6773-7873)
- Yi Lin (ORCID: https://orcid.org/0000-0002-1556-6416)
- Surbhi Sidana (ORCID: https://orcid.org/0000-0003-3288-7614)
- Efstathios Kastritis (ORCID: https://orcid.org/0000-0001-8191-5832)
- Frederick Lundry Locke (ORCID: https://orcid.org/0000-0001-9063-6691)
- Rahul Kumar Banerjee (ORCID: https://orcid.org/0000-0003-3781-5441)
- Darren Pan (ORCID: https://orcid.org/0000-0003-1668-9829)
- Danai Dima (ORCID: https://orcid.org/0000-0002-3587-7975)
- Hitomi Hosoya (ORCID: https://orcid.org/0000-0003-0475-9666)
- Shaji Kunnathu Kumar (ORCID: https://orcid.org/0000-0001-5392-9284)
- Jeries Kort (ORCID: https://orcid.org/0000-0001-9182-3931)
- Andrew Jay Portuguese (ORCID: https://orcid.org/0000-0003-1010-4578)
- Gliceida Galarza Fortuna (ORCID: https://orcid.org/0000-0002-1084-953X)
- Shahzad Raza (ORCID: https://orcid.org/0000-0002-2739-2265)
- Joaquín Martínez‐López (ORCID: https://orcid.org/0000-0001-7908-0063)
- Lekha Mikkilineni (ORCID: https://orcid.org/0009-0003-7698-5934)
- Hossam M. Ali (ORCID: https://orcid.org/0009-0006-3778-5499)
- Cindy Varga (ORCID: https://orcid.org/0000-0003-4882-5581)
- Larry Don Anderson (ORCID: https://orcid.org/0000-0002-6531-9595)
- Leyla Osman Shune (ORCID: https://orcid.org/0000-0003-1650-1873)
- Utkarsh Goel (ORCID: https://orcid.org/0000-0003-1663-0325)
- Shebli Atrash (ORCID: https://orcid.org/0000-0003-4547-7534)
- Omar Alexis Castaneda Puglianini (ORCID: https://orcid.org/0000-0003-0423-5870)
- Doris K. Hansen (ORCID: https://orcid.org/0000-0002-9813-3578)
- Murali Janakiram (ORCID: https://orcid.org/0000-0001-9323-8007)
- Noa Biran (ORCID: https://orcid.org/0000-0003-0693-4202)
- Hamza Hassan (ORCID: https://orcid.org/0000-0003-1775-2703)
- Hira S. Mian (ORCID: https://orcid.org/0000-0003-1584-1067)
- Aishwarya Sannareddy (ORCID: https://orcid.org/0009-0000-4779-6905)
- Douglas Weston Sborov (ORCID: https://orcid.org/0000-0003-4268-2698)
- Sireesha Asoori (ORCID: https://orcid.org/0009-0000-1488-8053)
- Krina K. Patel (ORCID: https://orcid.org/0000-0002-8894-027X)
- Kelley L. Julian (ORCID: https://orcid.org/0000-0002-2111-2461)
- Peter Michael Voorhees (ORCID: https://orcid.org/0000-0003-1661-718X)
- Oren Pasvolsky (ORCID: https://orcid.org/0000-0001-9193-0059)
- Kimberly M Green (ORCID: https://orcid.org/0009-0003-1150-5506)
- Chiung‐Yu Huang (ORCID: https://orcid.org/0000-0003-2313-3562)
- Saurabh Zanwar (ORCID: https://orcid.org/0000-0001-5074-8453)
- Rachid Baz (ORCID: https://orcid.org/0000-0003-4538-4733)
- Thomas G Martin (ORCID: https://orcid.org/0000-0003-2993-1979)
- Megan M. Herr (ORCID: https://orcid.org/0000-0001-5768-9396)
- Masooma Shifa Rana (ORCID: https://orcid.org/0000-0003-1731-085X)
- Christopher James Ferreri (ORCID: https://orcid.org/0000-0003-2997-4856)
- Emily C. Liang (ORCID: https://orcid.org/0000-0001-5790-4770)
- Lauren Cole Peres (ORCID: https://orcid.org/0000-0002-6620-8600)
- Rakesh Popat (ORCID: https://orcid.org/0000-0001-6553-4618)
- Ariel Felipe Grajales-Cruz (ORCID: https://orcid.org/0000-0003-0999-1771)
- Susan Bal (ORCID: https://orcid.org/0000-0002-8206-8919)
- James A. Davis (ORCID: https://orcid.org/0000-0001-7978-1652)
- Melissa Alsina (ORCID: https://orcid.org/0000-0003-4946-823X)
- Carlyn Rose C. Tan (ORCID: https://orcid.org/0000-0001-7922-2594)
- Andre De Menezes Silva Corraes (ORCID: https://orcid.org/0009-0001-8234-6755)
- Mrugakshi Dave (ORCID: https://orcid.org/0009-0004-7538-8502)
- Amrita Y. Krishnan (ORCID: https://orcid.org/0000-0002-8484-175X)
- Lisa Lee
- Raffaela Cassano Cassano
- Tiffany Richards
- Binod Dhakal
Institutions
- Roswell Park Comprehensive Cancer Center (US)
- City Of Hope National Medical Center (US)
- Cleveland Clinic (US)
- Hackensack University Medical Center (US)
- Mayo Clinic (US)
- Memorial Sloan Kettering Cancer Center (US)
- University College London Hospitals NHS Foundation Trust (GB)
- The University of Texas MD Anderson Cancer Center (US)
- Medical University of South Carolina (US)
- University of California, San Francisco (US)
- University of Ostrava (CZ)
- National and Kapodistrian University of Athens (GR)
- University of Utah (US)
- Juravinski Cancer Centre (CA)
- Huntsman Cancer Institute (US)
- Moffitt Cancer Center (US)
- University of Alabama at Birmingham (US)
- University Hospital Ostrava (CZ)
- Fred Hutch Cancer Center (US)
- Spanish National Cancer Research Centre (ES)
- Levine Cancer Institute (US)
- City of Hope (US)
- Birmingham VA Medical Center (US)
- University of Kansas Medical Center (US)
- Stanford Medicine (US)
- International Myeloma Foundation (US)
- UCSF Helen Diller Family Comprehensive Cancer Center (US)
- Wake Forest University (US)
- The University of Texas Southwestern Medical Center (US)
- Stanford University (US)
- McMaster University (CA)
Publication Details
- Journal
- Journal of Clinical Oncology
- Published
- 2026-11-13
- DOI
- https://doi.org/10.1200/jco-26-01039
- Primary Topic
- Multiple Myeloma Research and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00